Everolimus (EVE) is a mammalian target of rapamycin inhibitor (mTOR-I) widely used in transplantation that may determine some severe adverse events, including pulmonary fibrosis. The pathogenic mechanism of mTOR-I-associated pulmonary toxicity is still unclear, but epithelial to mesenchymal transition (EMT) of bronchial/pulmonary cells may play a role.
Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation
TOMEI, Paola;MASOLA, Valentina;Granata, Simona;Bellin, Gloria;Ficial, Miriam;Gambaro, Giovanni;CHILOSI, Marco;LUPO, Antonio;Zaza, Gianluigi
2016-01-01
Abstract
Everolimus (EVE) is a mammalian target of rapamycin inhibitor (mTOR-I) widely used in transplantation that may determine some severe adverse events, including pulmonary fibrosis. The pathogenic mechanism of mTOR-I-associated pulmonary toxicity is still unclear, but epithelial to mesenchymal transition (EMT) of bronchial/pulmonary cells may play a role.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
J Nephrology 2016.pdf
solo utenti autorizzati
Tipologia:
Versione dell'editore
Licenza:
Accesso ristretto
Dimensione
4.22 MB
Formato
Adobe PDF
|
4.22 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
